Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins.

摘要: Background Statin intolerance is a medical condition often leading patients to nonadherence the prescribed therapy or relevant reduction of statin dosage. Both situations determine totally partially uncontrolled lipid profile, and these conditions unquestionably increase risk cardiovascular events. Methods We enrolled hypercholesterolemic, type 2 diabetic complaining statins. Some them had reduced dose 'until disappearance symptoms'; others opted for treatment with ezetimibe; yet were not undergoing any at all. All three groups then given fixed combination berberine silymarin (Berberol(®)), known from previous papers be able control both lipidic glycemic profiles. Results The tested product as single add-on low-dose ezetimibe triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, glycosylated hemoglobin in significant manner without inducing toxicity that might somehow ascribed statin-intolerant condition. Conclusion Our study demonstrates use Berberol(®), administered subjects affected by diabetes hypercholesterolemia safe effective tool capable improving patients'